Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Leukemia, Myeloid, Acute 32Leukemia, Lymphocytic, Chronic, B-Cell 22Myelodysplastic Syndromes 9Lymphoma, Follicular 8Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Recurrence 5Leukemia, Myelomonocytic, Chronic 5Multiple Myeloma 4Chromosome 17 deletion 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid 3Hematologic Neoplasms 3Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Breast Neoplasms 2Tumor Lysis Syndrome 1Small Cell Lung Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myeloid Malignancy 1Myeloid Malignancies 1

Interventions

Dexamethasone 277Lenalidomide 155Bortezomib 152Cyclophosphamide 115Melphalan 107Calcium Dobesilate 107fludarabine phosphate 70carfilzomib 61pomalidomide 55Peripheral Blood Stem Cell Transplantation 53Whole-Body Irradiation 52Mycophenolic Acid 52Granulocyte Colony-Stimulating Factor 52Filgrastim 52daratumumab 46fludarabine 43Tacrolimus 41ixazomib 40Busulfan 40Thalidomide 36Cyclosporine 32dexamethasone acetate 26Stem Cell Transplantation 26Antilymphocyte Serum 25dexamethasone 21-phosphate 22plerixafor 20auricularum 20belantamab mafodotin 19Prednisone 19Etoposide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Multiple Myeloma × venetoclax × Clear all
NCT02755597 2023-08-22

Bellini

AbbVie

Phase 3 Completed
291 enrolled 24 charts
Plasma cell

Multiple Myeloma

NCT01794520 2023-04-10

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

AbbVie

Phase 1/2 Completed
117 enrolled 29 charts
Plasma cell

Multiple Myeloma

NCT03312530 2023-02-28

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Hoffmann-La Roche

Phase 1/2 Completed
49 enrolled 24 charts
Plasma cell

Multiple Myeloma

NCT03567616 2021-06-30

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

AbbVie

Phase 2 Terminated
8 enrolled 12 charts
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡